Retinopathy of prematurity (ROP) is the leading cause of visual disability from early childhood. Foreign researchers and clinicians are focused on studying a new pharmacological method of treatment of active RN using anti-VEGF drugs, which was a reason that prompted updates in the International Classification of Retinopathy of Prematurity (ICROP) in 2021. The second part of the article presents new terms recommended by the Committee for the ICROP: “regression,” which refers to the involution and resolution of the disease, and “reactivation,” which denotes a recurrence of signs in the acute phase. Notably, the latest edition of the ICROP requires a deep understanding and accurate application by domestic specialists treating ROP. This contributes to the standardization of therapeutic and diagnostic processes, therefore, improving the quality of ROP treatment in Russia.
Read full abstract